BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Hong Kong

Akeso Completes Patient Enrollment for Phase III Trial of Cadonilimab as Adjuvant Therapy for Hepatocellular Carcinoma

Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinic...

March 06, 2025 | News

Akeso Enrolls First Patient in Phase I Trial for HER3-Targeting ADC AK138D1 in Australia

Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in...

February 28, 2025 | News

Ping An Health Launches AI-Powered "Ping An Xin Yi" Digital Doctor for 24/7 Smart Healthcare

Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) recently annou...

February 27, 2025 | News

Hong Kong Pharma Stocks Surge as AIM Vaccine Secures U.S. Clinical Approval for mRNA RSV Vaccine

The stocks in the Hong Kong pharmaceutical sector have recently shown an upward trend. As global capital flows positively into the pharmaceutical...

February 27, 2025 | News

Akeso, Summit Therapeutics, and Pfizer Join Forces to Advance Ivonescimab-ADC Combinations in Solid Tumor Trials

Akeso, Inc. announced that its partner on ivonescimab, Summit Therapeutics Inc. has entered into a clinical trial collaboration with Pfizer Inc...

February 25, 2025 | News

Akeso Begins Phase III Trial of Ivonescimab for First-Line Treatment of Advanced Triple-Negative Breast Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, ran...

February 24, 2025 | News

Akeso Doses First Patient in Phase III Trial of Ivonescimab for First-Line Treatment of Triple-Negative Breast Cancer

Akeso, Inc. announced the company has successfully enrolled the first patient in its multicenter, randomized, double-blind Phase III clinical trial of...

February 21, 2025 | News

Hong Kong Genome Institute Partners with Global Leaders to Advance Genomic Medicine at International Symposium

HKGI Partners with Global Leaders to Chart a Course for Healthcare Transformation HONG KONG, Feb. 19, 2025 /PRNewswire/ -- Genomic medicine...

February 20, 2025 | News

Ascletis’ ASC30 Oral Tablet Shows Promising Weight Loss in U.S. Phase Ib Obesity Trial

- ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from baseline after 28-day treatment in multiple ascendi...

February 20, 2025 | News

IASO Biotherapeutics’ New Drug Application for Equecabtagene Autoleucel Accepted by Hong Kong Department of Health

IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative ce...

February 17, 2025 | News

Akeso Initiates Phase 3 Trial in China for Cadonilimab as Consolidation Therapy in Advanced NSCLC

Akeso, Inc. announced the recent completion of the first patient enrollment in the Phase 3 randomized, double-blind, multicenter clinical trial (COMPASSION...

February 13, 2025 | News

AIM Vaccine Leads China's mRNA Innovation, Submits Breakthrough Shingles Vaccine for Clinical Trials

AIM Vaccine Co, a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA s...

February 12, 2025 | News

Bowtie, Gleneagles Hospital, and Pfizer Hong Kong Unite to Combat Migraine Misconceptions

Bowtie, Hong Kong's pioneering virtual insurer, has joined forces with Gleneagles Hospital Hong Kong and Pfizer Hong Kong to la...

February 10, 2025 | News

Akeso Completes Global Phase III Enrollment for Ivonescimab in Squamous NSCLC

Akeso, Inc. is excited to announce the completion of patient enrollment in the global Phase III clinical trial (HARMONi-6/AK112-306) evaluating ivonescimab...

February 06, 2025 | News

Stay Connected